Market Cap
$3.7B
TARS
Tarsus Pharmaceuticals, Inc.
$73.85 ▼ -2.13%
Prev close $75.46Market cap$3.7B
ConsensusStrong Buy
12-mo target$99.50 (+34.7%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (3 insiders)High Impact Filing (7/10)26 New Institutional Positions22 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on TARS right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (93%)
Inst. Holders
50 funds
Inst. Value
$2.1B
Inst. Activity
26 buys / 22 sells
Insider Activity
$0.00 buy / $8.1M sell
Insider Net $
-$8.1M
SEC Reports
12
Press Releases
1
Price chart 30d -10.8%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 15, 2026 Insider
PYOTT DAVID E I acquired via exercise 201 shares
Director
Sep 15, 2026 Insider
YARNO WENDY L acquired via exercise 302 shares
Director
Sep 15, 2026 Insider
Sep 10, 2026 SEC LINK WILLIAM J PHD sold 11,675 shares
Director @ $78.33 ($914.5K)
Three top insiders (CEO, COO, CMO) sold shares totaling ~$2.5M over a one-week window ending September 4, 2026. The tota
CLUSTER — Impact 3/10
CEO Bobak Azamian and CMO Elizabeth Yeu sold a combined $928K in TARS shares over two days. The total represents just 0.
CLUSTER — Impact 2/10
Sep 4, 2026 short_volume
Sep 2, 2026 SEC Short Volume: TARS — 61.6% short (0.4M / 0.7M)
Short: 435,890 | Exempt: 0 | TRF Vol: 707,993 | Short Ratio: 61.6% | Off-exchange volume (dark pool
Former officer Aziz Mottiwala filed a Form 144 to sell 8,000 shares (~$654k) of Tarsus Pharmaceuticals. This follows sub
144 — Impact 4/10
Aug 26, 2026 Event
HSR Early Termination: Tarsus Pharmaceuticals, Inc.; Leonide Saad
The FTC granted early termination of the HSR Act waiting period for a transaction involving Tarsus P
Analyst ratings buy % +5.7%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
93% rate it Buy or better · 14 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 8, 2026 | Jefferies | MAINTAIN | Buy | 53% |
| Aug 12, 2026 | Oppenheimer | MAINTAIN | Outperform | 52% |
| Jul 31, 2026 | Mizuho | MAINTAIN | Outperform | 52% |
| Jul 21, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| Jul 9, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 4, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| Aug 1, 2026 | 7 | 7 | 1 | 0 | 0 | 93% | |
| Jul 1, 2026 | 7 | 7 | 1 | 0 | 0 | 93% | |
| Jun 1, 2026 | 7 | 7 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 7 | 7 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 7 | 7 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 7 | 7 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 7 | 7 | 2 | 0 | 0 | 88% |
Price targets
Where 10 covering analysts think TARS trades over the next 12 months.
$99.50 +34.7% upside Strong Buy
Current$73.85 Low$84.00 Median$100.00 High$116.00 10 analysts
$84.00$116.00
Analyst rating Strong Buy· 1.1/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
12 SEC filing reports analyzed · 2 bullish, 3 bearish, 2 mixed, 5 neutral · avg impact 4.4/10.Plus 1 press releases.
NEUTRALCLUSTER3/10
Three top insiders (CEO, COO, CMO) sold shares totaling ~$2.5M over a one-week window ending Septemb
Sep 10, 2026
NEUTRALCLUSTER2/10
CEO Bobak Azamian and CMO Elizabeth Yeu sold a combined $928K in TARS shares over two days. The tota
Sep 4, 2026
BEARISH1444/10
Former officer Aziz Mottiwala filed a Form 144 to sell 8,000 shares (~$654k) of Tarsus Pharmaceutica
Sep 2, 2026
BEARISH1445/10
Former officer Aziz Mottiwala filed a Form 144 notice to sell 77,698 shares (~$5.75M) of Tarsus Phar
Sep 1, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 4, 2026
short_volume
Short Volume: TARS — 61.6% short (0.4M / 0.7M)
Short: 435,890 | Exempt: 0 | TRF Vol: 707,993 | Short Ratio: 61.6% | Off-exchange volume (dark pool + OTC)
Aug 26, 2026
Enforcement
HSR Early Termination: Tarsus Pharmaceuticals, Inc.; Leonide Saad
The FTC granted early termination of the HSR Act waiting period for a transaction involving Tarsus Pharmaceuticals, Inc.; Leonide Saad.
Aug 12, 2026
short_volume
Short Volume: TARS — 61.2% short (0.3M / 0.5M)
Short: 320,073 | Exempt: 0 | TRF Vol: 523,072 | Short Ratio: 61.2% | Off-exchange volume (dark pool + OTC)
Aug 6, 2026
earnings
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
Generated second quarter 2026 XDEMVY ® net product sales of $173.9 million, an increase of more than 69% year-over-year
Aug 6, 2026
offering
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (“Tarsus”) today announced that it has entered into a se
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-1.77 | $-2.23–$-1.46 | -488.9% | -15.2% | 0↑ 2↓ | $0.2B | 3 |
| Next Q | $-3.39 | $-9.57–$0.02 | -1596.7% | -7612.1% | — | $0.2B | 3 |
| Current FY | $-5.77 | $-11.63–$-2.15 | -262.9% | -170.6% | 0↑ 1↓ | $0.7B | 3 |
| Next FY | $-0.36 | $-1.76–$1.04 | 93.8% | -115.5% | 0↑ 1↓ | $0.9B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-1.767 | — |
| 7d ago | $-1.537 | -0.230 |
| 30d ago | $-1.534 | -0.233 |
| 60d ago | $-1.835 | +0.068 |
| 90d ago | $-0.197 | -1.570 |
Institutional ownership
Which big funds own TARS (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $2.1B total value (32,624,271 shares) as of 2026-Q2. Top holders: BlackRock,, RTW, Jupiter. Net buying activity: 26 institutions added/increased vs 22 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 3,856,137 | $242.7M | 11.8% | — |
| RTW INVESTMENTS, LP | 3,357,059 | $211.3M | 10.3% | — |
| Jupiter Topco LLC | 2,808,796 | $176.8M | 8.6% | — |
| MORGAN STANLEY | 1,827,082 | $115.0M | 5.6% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,793,064 | $112.9M | 5.5% | — |
| JENNISON ASSOCIATES LLC | 1,663,655 | $104.7M | 5.1% | — |
| MILLENNIUM MANAGEMENT LLC | 1,427,124 | $89.8M | 4.4% | DOUBLED +152.8% |
| BANK OF AMERICA CORP /DE/ | 1,193,182 | $75.1M | 3.7% | ADD +57.5% |
| GEODE CAPITAL MANAGEMENT, LLC | 1,105,689 | $69.6M | 3.4% | — |
| STATE STREET CORP | 1,072,951 | $67.5M | 3.3% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | DOUBLED | 564,579 | 1,427,124 | +152.8% | $89.8M |
| Assenagon Asset Management S.A. | TRIM | 1,280,194 | 947,495 | -26.0% | $59.6M |
| GOLDMAN SACHS GROUP INC | ADD | 439,626 | 742,693 | +68.9% | $46.7M |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | NEW | — | 427,008 | — | $26.9M |
| WASATCH ADVISORS LP | NEW | — | 368,568 | — | $23.2M |
| DRIEHAUS CAPITAL MANAGEMENT LLC | TRIM | 926,125 | 317,576 | -65.7% | $20.0M |
| CITADEL ADVISORS LLC | ADD | 163,997 | 241,737 | +47.4% | $15.2M |
| BNP PARIBAS FINANCIAL MARKETS | TRIM | 303,509 | 201,624 | -33.6% | $12.7M |
| MACKENZIE FINANCIAL CORP | NEW | — | 191,428 | — | $12.0M |
| JPMORGAN CHASE & CO | DOUBLED | 30,478 | 139,981 | +359.3% | $8.7M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 50 transactions. Net -$8.1M — $0.00 bought, $8.1M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | PYOTT DAVID E I | Director | EXERCISE | 201 | — | — |
| Sep 15, 2026 | YARNO WENDY L | Director | EXERCISE | 302 | — | — |
| Sep 15, 2026 | LINK WILLIAM J PHD | Director | SELL | 11,675 | $78.33 | $914.5K |
| Sep 15, 2026 | LINK WILLIAM J PHD | Director | SELL | 66 | $80.01 | $5.3K |
| Sep 15, 2026 | LINK WILLIAM J PHD | Director | EXERCISE | 201 | — | — |
| Sep 15, 2026 | LINK WILLIAM J PHD | Director | SELL | 759 | $79.00 | $60.0K |
| Sep 4, 2026 | Lin Elizabeth Yeu | Chief Medical Officer | SELL | 5,387 | $85.00 | $457.9K |
| Sep 4, 2026 | Lin Elizabeth Yeu | Chief Medical Officer | SELL | 1,590 | $90.00 | $143.1K |
| Sep 4, 2026 | Lin Elizabeth Yeu | Chief Medical Officer | SELL | 1,590 | $85.00 | $135.2K |
| Sep 4, 2026 | Neervannan Seshadri | Chief Operating Officer | SELL | 4,564 | $85.00 | $387.9K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for TARS.
Shares short
6,127,884
Settlement Sep 15, 2026
Change vs prior
+1.9%
Semi-monthly cycle
Days to cover
6.6
At avg daily volume
Of shares outstanding
≈13.1%
Estimate — not % of float
All TARS filing & press-release reports (13)
- CLUSTER reportSep 10, 2026
- CLUSTER reportSep 4, 2026
- 144 reportSep 2, 2026
- 144 reportSep 1, 2026
- 144 reportAug 19, 2026
- 8-K reportAug 6, 2026
- 8-K reportAug 6, 2026
- 8-K reportAug 6, 2026
- PRESS-RELEASE reportAug 6, 2026
- PRESS-RELEASE reportAug 6, 2026
- 144 reportJun 16, 2026
- 144 reportJun 15, 2026
- CLUSTER reportMar 24, 2026